Show simple item record

dc.contributor.authorYu, K
dc.contributor.authorTaylor, J
dc.contributor.authorPathmanaban, O
dc.contributor.authorYoushani, A
dc.contributor.authorBeyit, D
dc.contributor.authorDutko-Gwozdz, J
dc.contributor.authorBenson, R
dc.contributor.authorGriffiths, G
dc.contributor.authorPeers, I
dc.contributor.authorCueppens, P
dc.contributor.authorTelfer, B
dc.contributor.authorWilliams, K
dc.contributor.authorMcBain, Catherine A
dc.contributor.authorKamaly-Asl, I
dc.contributor.authorBigger, B
dc.date.accessioned2018-04-28T20:48:59Z
dc.date.available2018-04-28T20:48:59Z
dc.date.issued2018
dc.identifier.citationHigh content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma. 2018, 13(3): e0193694 PLoS Oneen
dc.identifier.issn1932-6203
dc.identifier.pmid29499065
dc.identifier.doi10.1371/journal.pone.0193694
dc.identifier.urihttp://hdl.handle.net/10541/620915
dc.description.abstractGlioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes remain poor. First line treatment is well established, however disease invariably recurs and improving prognosis is challenging. With the aim of personalizing therapy at recurrence, we have established a high content screening (HCS) platform to analyze the sensitivity profile of seven patient-derived cancer stem cell lines to 83 FDA-approved chemotherapy drugs, with and without irradiation.
dc.language.isoenen
dc.rightsArchived with thanks to PloS oneen
dc.titleHigh content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.en
dc.typeArticleen
dc.contributor.departmentBrain Tumour Research Group, Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology & Regenerative Medicine, University of Manchester, Manchester, United Kingdomen
dc.identifier.journalPloS Oneen
refterms.dateFOA2018-12-17T15:19:59Z
html.description.abstractGlioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes remain poor. First line treatment is well established, however disease invariably recurs and improving prognosis is challenging. With the aim of personalizing therapy at recurrence, we have established a high content screening (HCS) platform to analyze the sensitivity profile of seven patient-derived cancer stem cell lines to 83 FDA-approved chemotherapy drugs, with and without irradiation.


Files in this item

Thumbnail
Name:
journal.pone.0193694.pdf
Size:
8.521Mb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record